Ads
related to: tecfidera- Copay Program
Explore Important Financial And
Copay Information.
- Financial Support
Understand Financial & Insurance
Support For Your Treatment.
- How VUMERITY® Works
Learn More About How
VUMERITY® Is Thought To Work.
- VUMERITY® Support Program
Join The Support Program To Receive
Tips, Tools And Assistance.
- Resources for Care
Partners. Explore
RMS Articles, Tools & Advice.
- Talk To Your Doctor
Download A Discussion Guide
To Bring To Your Next Appointment
- Copay Program
Search results
Biogen holds onto Tecfidera market in Europe for a little longer
BioPharma Dive via Yahoo Finance· 6 months agoA decision by European regulators to revoke approvals for five generic versions of Biogen's multiple...
If You Invested $25,000 in Biogen in 2018, This Is How Much You Would Have Today
Motley Fool· 1 year agoFive years ago, pharmaceutical manufacturer Biogen (NASDAQ: BIIB) had a growing business, and...
US Supreme Court Turns Away Biogen's Last Effort To Reinstate Tecfidera Patent
Benzinga via Yahoo Finance· 2 years agoThe U.S. Supreme Court decided not to hear the case related to reinstating the patent of Biogen...
Biogen Inc. (BIIB) Down 2.3% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 1 year agoA month has gone by since the last earnings report for Biogen Inc. (BIIB). Shares have lost about...
Biogen (BIIB) Beats on Q2 Earnings & Sales, Ups 2022 Guidance
Zacks via Yahoo Finance· 2 years agoBiogen BIIB reported second-quarter 2022 earnings per share (EPS) of $5.25, which significantly beat...
U.S. Supreme Court turns away Biogen bid to reinstate MS drug patent
Reuters via Yahoo News· 2 years agoWASHINGTON (Reuters) -The U.S. Supreme Court on Monday declined to hear Biogen Inc's bid to win...
Why Is Biogen Inc. (BIIB) Up 8.2% Since Last Earnings Report?
Zacks via Yahoo Finance· 2 years agoA month has gone by since the last earnings report for Biogen Inc. (BIIB). Shares have added about...
Biogen (BIIB) Q4 Earnings & Sales Miss Estimates, Stock Falls
Zacks via Yahoo Finance· 4 months agoBiogen BIIB reported fourth-quarter 2023 adjusted earnings per share (EPS) of $2.95, which missed...
Europe revokes marketing authorization for generic versions of Biogen's MS drug
Reuters via AOL· 6 months agoWhile the patent for Biogen's drug has expired in the United States, it had scored a win in Europe...
Will Biogen (BIIB) Beat Estimates This Earnings Season?
Zacks via Yahoo Finance· 1 year agoWe expect Biogen BIIB to beat expectations when it reports fourth-quarter and full-year 2022 results...
Ads
related to: tecfidera